2,4-dichloro-N-(3-fluoro-4-quinolin-3-yloxyphenyl)benzenesulfonamide | 1422348-22-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,4-dichloro-N-(3-fluoro-4-quinolin-3-yloxyphenyl)benzenesulfonamide
• CAS: 1422348-22-8
• 化学式: C₂₁H₁₃Cl₂FN₂O₃S
• 分子量: 463.316
• InChiKey: ZTGVHNBZFLSODQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-羟基喹啉 在 吡啶 、 tin(II) chloride dihdyrate 、 caesium carbonate 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 2,4-dichloro-N-(3-fluoro-4-quinolin-3-yloxyphenyl)benzenesulfonamide
  参考文献：
  名称：

  Discovery of INT131: A selective PPARγ modulator that enhances insulin sensitivity

  摘要：

  PPAR gamma is a member of the nuclear hormone receptor family and plays a key role in the regulation of glucose homeostasis. This Letter describes the discovery of a novel chemical class of diarylsulfonamide partial agonists that act as selective PPAR gamma modulators (SPPAR gamma Ms) and display a unique pharmacological profile compared to the thiazolidinedione (TZD) class of PPAR gamma full agonists. Herein we report the initial discovery of partial agonist 4 and the structure-activity relationship studies that led to the selection of clinical compound INT131 (3), a potent PPAR gamma partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.11.058

文献信息

• [EN] SULFONAMIDE DERIVATIVES, COMPOSITIONS COMPRISING SAME AND USES THEREOF IN THE TREATMENT OF CANCERS<br/>[FR] DÉRIVÉS DE SULFONAMIDE, COMPOSITIONS LES COMPRENANT ET LEURS UTILISATIONS DANS LE TRAITEMENT DE CANCERS
  申请人：[en]NATIONAL CANCER CENTER

  公开号：WO2022144780A1

  公开（公告）日：2022-07-07

  Described herein are sulfonamide derivatives of Formula (I) capable of inhibiting RNA dependent RNA polymerase (RdRP) activity of cancer cells. Also described are pharmaceutical compositions comprising these compounds and the uses thereof in the prophylaxis and/or treatment of cancers, including intractable solid cancers and stem cells cancer. The pharmaceutical composition may further comprise at least one of an hormonal therapeutic agent, a chemotherapeutic agent, an immunotherapeutic agent, a pharmaceutical agent inhibiting the action of cell growth factor and a pharmaceutical agent inhibiting the action of cell growth factor receptor.
• Discovery of INT131: A selective PPARγ modulator that enhances insulin sensitivity
  作者：Joshua P. Taygerly、Lawrence R. McGee、Steven M. Rubenstein、Jonathan B. Houze、Timothy D. Cushing、Yang Li、Alykhan Motani、Jin-Long Chen、Walter Frankmoelle、Guosen Ye、Marc R. Learned、Juan Jaen、Shichang Miao、Pieter B. Timmermans、Martin Thoolen、Patrick Kearney、John Flygare、Holger Beckmann、Jennifer Weiszmann、Michelle Lindstrom、Nigel Walker、Jinsong Liu、Donna Biermann、Zhulun Wang、Atsushi Hagiwara、Tetsuya Iida、Hisateru Aramaki、Yuki Kitao、Hisashi Shinkai、Noboru Furukawa、Jun Nishiu、Motonao Nakamura

  DOI：10.1016/j.bmc.2012.11.058

  日期：2013.2

  PPAR gamma is a member of the nuclear hormone receptor family and plays a key role in the regulation of glucose homeostasis. This Letter describes the discovery of a novel chemical class of diarylsulfonamide partial agonists that act as selective PPAR gamma modulators (SPPAR gamma Ms) and display a unique pharmacological profile compared to the thiazolidinedione (TZD) class of PPAR gamma full agonists. Herein we report the initial discovery of partial agonist 4 and the structure-activity relationship studies that led to the selection of clinical compound INT131 (3), a potent PPAR gamma partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs. (C) 2012 Elsevier Ltd. All rights reserved.